Literature DB >> 21537013

Protein binding: do we ever learn?

Markus A Zeitlinger1, Hartmut Derendorf, Johan W Mouton, Otto Cars, William A Craig, David Andes, Ursula Theuretzbacher.   

Abstract

Although the influence of protein binding (PB) on antibacterial activity has been reported for many antibiotics and over many years, there is currently no standardization for pharmacodynamic models that account for the impact of protein binding of antimicrobial agents in vitro. This might explain the somewhat contradictory results obtained from different studies. Simple in vitro models which compare the MIC obtained in protein-free standard medium versus a protein-rich medium are prone to methodological pitfalls and may lead to flawed conclusions. Within in vitro test systems, a range of test conditions, including source of protein, concentration of the tested antibiotic, temperature, pH, electrolytes, and supplements may influence the impact of protein binding. As new antibiotics with a high degree of protein binding are in clinical development, attention and action directed toward the optimization and standardization of testing the impact of protein binding on the activity of antibiotics in vitro become even more urgent. In addition, the quantitative relationship between the effects of protein binding in vitro and in vivo needs to be established, since the physiological conditions differ. General recommendations for testing the impact of protein binding in vitro are suggested.

Mesh:

Substances:

Year:  2011        PMID: 21537013      PMCID: PMC3122431          DOI: 10.1128/AAC.01433-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  114 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  The influence of protein binding on the antibacterial activity of faropenem against Haemophilus influenzae.

Authors:  I Gustafsson; O Cars
Journal:  Clin Microbiol Infect       Date:  2004-10       Impact factor: 8.067

3.  Effect of ertapenem protein binding on killing of bacteria.

Authors:  David E Nix; Kathryn R Matthias; Emily C Ferguson
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

4.  Clinical pharmacology of the new penicillins. 1. The importance of serum protein binding in determining antimicrobial activity and concentration in serum.

Authors:  C M Kunin
Journal:  Clin Pharmacol Ther       Date:  1966 Mar-Apr       Impact factor: 6.875

5.  pK change of imidazole groups in bovine serum albumin due to the conformational change at neutral pH.

Authors:  B J Harmsen; S H De Bruin; L H Janssen; J F Rodrigues de Miranda; G A Van Os
Journal:  Biochemistry       Date:  1971-08-17       Impact factor: 3.162

6.  Determination of unbound ceftriaxone in rat blood by on-line microdialysis and microbore liquid chromatography.

Authors:  T H Tsai; F C Cheng; L C Hung; C F Chen
Journal:  Int J Pharm       Date:  1999-12-20       Impact factor: 5.875

7.  Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.

Authors:  Sharath S Hegde; Noe Reyes; Tania Wiens; Nicole Vanasse; Robert Skinner; Julia McCullough; Koné Kaniga; John Pace; Roger Thomas; Jeng-Pyng Shaw; Glen Obedencio; J Kevin Judice
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.

Authors:  F Scaglione; J W Mouton; R Mattina; F Fraschini
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

9.  Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model.

Authors:  Raymond Cha; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2004-05-18       Impact factor: 5.790

10.  Pharmaceutical-grade albumin: impaired drug-binding capacity in vitro.

Authors:  Harald Olsen; Anders Andersen; Arve Nordbø; Ulf E Kongsgaard; Ole P Børmer
Journal:  BMC Clin Pharmacol       Date:  2004-03-29
View more
  77 in total

1.  Protein Binding of First-Line Antituberculosis Drugs.

Authors:  Wael A Alghamdi; Mohammad H Al-Shaer; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

2.  Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue.

Authors:  Nathan D Pfeifer; Kevin B Harris; Grace Zhixia Yan; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2013-08-29       Impact factor: 3.922

3.  Cloxacillin concentrations in serum, subcutaneous fat, and muscle in patients with chronic critical limb ischemia.

Authors:  T B Jonsson; T K Nilsson; L H Breimer; J Schneede; B Arfvidsson; L Norgren
Journal:  Eur J Clin Pharmacol       Date:  2014-05-27       Impact factor: 2.953

Review 4.  Nonlinear Protein Binding: Not What You Think.

Authors:  Amelia N Deitchman; Ravi Shankar Prasad Singh; Hartmut Derendorf
Journal:  J Pharm Sci       Date:  2018-04-04       Impact factor: 3.534

Review 5.  Accessing analytes in biofluids for peripheral biochemical monitoring.

Authors:  Jason Heikenfeld; Andrew Jajack; Benjamin Feldman; Steve W Granger; Supriya Gaitonde; Gavi Begtrup; Benjamin A Katchman
Journal:  Nat Biotechnol       Date:  2019-02-25       Impact factor: 54.908

Review 6.  Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Authors:  Daniel Gonzalez; Stephan Schmidt; Hartmut Derendorf
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

Review 7.  Tactics for preclinical validation of receptor-binding radiotracers.

Authors:  Susan Z Lever; Kuo-Hsien Fan; John R Lever
Journal:  Nucl Med Biol       Date:  2016-09-03       Impact factor: 2.408

8.  Thioridazine inhibits gene expression control of the cell wall signaling pathway (CWI) in the human pathogenic fungus Paracoccidioides brasiliensis.

Authors:  Daniela Leite Jabes; Ana Claudia de Freitas Oliveira; Valquíria Campos Alencar; Fabiano Bezerra Menegidio; Débora Liliane Souza Reno; Daiene Souza Santos; David Aciole Barbosa; Renata Ozelami Vilas Boas; Rodrigo Luiz de Oliveira Rodrigues Cunha; Tiago Rodrigues; Regina Costa de Oliveira; Luiz R Nunes
Journal:  Mol Genet Genomics       Date:  2016-03-08       Impact factor: 3.291

9.  Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure.

Authors:  B Seetharamsingh; Remya Ramesh; Santoshkumar S Dange; Pankaj V Khairnar; Smita Singhal; Dilip Upadhyay; Sridhar Veeraraghavan; Srikant Viswanadha; Swaroop Vakkalanka; D Srinivasa Reddy
Journal:  ACS Med Chem Lett       Date:  2015-10-26       Impact factor: 4.345

10.  Antibacterial activity of resazurin-based compounds against Neisseria gonorrhoeae in vitro and in vivo.

Authors:  Deanna M Schmitt; Kristie L Connolly; Ann E Jerse; Melinda S Detrick; Joseph Horzempa
Journal:  Int J Antimicrob Agents       Date:  2016-07-19       Impact factor: 5.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.